Rumors Were True – Again: Abbott Did Try To Pull Out Of Alere Deal
This article was originally published in Clinica
Alere confirmed analysts’ suspicions that Abbott Laboratories is reticent about its planned $5.8bn takeover of the embattled diagnostics company, but the deal appears to be back on track, for now.
You may also be interested in...
The company says the matters under investigation are immaterial, but the stock market disagrees, taking about a billion dollars from embattled diagnostics company in under a half-hour.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.